Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Prapassorn ThirasastrThomas Lee SuttonCissimol P JosephHeather LinBehrang AminiSkye C MayoDejka AraujoRobert S BenjaminAnthony P ConleyJonathan A LivingstonJoseph LudwigShreyaskumar PatelRavin RatanVinod RaviMaria A ZarzourElise F Nassif HaddadMichael S NakazawaXiao ZhouMichael C HeinrichNeeta SomaiahPublished in: Cancers (2024)
Ripretinib and avapritinib have demonstrated activity in the late-line treatment of gastrointestinal stomal tumors (GISTs). We investigated whether patients previously treated with ripretinib benefit from avapritinib, and vice versa. Patients diagnosed with metastatic/unresectable GIST and treated with both drugs at two institutions in 2000-2021 were included. Patients were grouped by drug sequence: ripretinib-avapritinib (RA) or avapritinib-ripretinib (AR). Radiographic response was evaluated using RECIST 1.1. Kaplan-Meier and log-rank tests were used to compare time-to-progression (TTP) and overall survival (OS). Thirty-four patients (17 per group) were identified, with a median age of 48 years. The most common primary site was the small bowel (17/34, 50%), followed by the stomach (10/34, 29.4%). Baseline characteristics and tumor mutations were not significantly different between groups. Response rates (RRs) for ripretinib were 18% for RA and 12% for AR; RRs for avapritinib were 12% for AR and 18% for RA. Median TTPs for ripretinib were 3.65 months (95%CI 2-5.95) for RA and 4.73 months (1.87-15.84) for AR. Median TTPs for avapritinib were 5.39 months (2.86-18.99) for AR and 4.11 months (1.91-11.4) for RA. Median OS rates following RA or AR initiation were 29.63 (95%CI 13.8-50.53) and 33.7 (20.03-50.57) months, respectively. Both ripretinib and avapritinib were efficacious in the late-line treatment of GIST, with no evidence that efficacy depended on sequencing.
Keyphrases
- end stage renal disease
- newly diagnosed
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- emergency department
- small cell lung cancer
- disease activity
- metabolic syndrome
- radiation therapy
- mass spectrometry
- systemic sclerosis
- adipose tissue
- interstitial lung disease
- systemic lupus erythematosus
- high speed
- amino acid